Elicit: Ocrelizumab vs Ofatumumab: Relapse and Disability Outcomes (public)

Ocrelizumab vs Ofatumumab: Relapse and Disability Outcomes

Research report

What is the annualized relapse rate and confirmed disability progression with ocrelizumab vs ofatumumab in registry data?

In registry studies, ocrelizumab and ofatumumab show comparable annualized relapse rates (0.059 vs 0.038, p = 0.185) and both achieve 0% confirmed disability progression at 12 months.

Abstract

Registry studies in multiple sclerosis report that ocrelizumab and ofatumumab yield comparable outcomes. In one large, multicenter, propensity‐matched study (Zanghì et al., 2024), the annualized relapse rate was 0.059 with ocrelizumab versus 0.038 with ofatumumab (p = 0.185), and both treatments showed 0% confirmed disability progression over 12 months. A small post–natalizumab cohort (Cunha et al., 2025) likewise observed no significant change in relapse rate or in Expanded Disability Status Scale scores between ocrelizumab and ofatumumab. Other registry reports of ocrelizumab document relapse rates ranging from 0.014 to 0.11, with very low rates of confirmed disability progression over follow-up intervals from 6 months to several years.

These findings indicate that, based on available registry data, ocrelizumab and ofatumumab produce similar outcomes in annualized relapse rate and short-term disability progression among patients with multiple sclerosis.

Methods

We analyzed 40 sources from an initial pool of 999, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

Paper search

Using your research question “What is the annualized relapse rate and confirmed disability progression with ocrelizumab vs ofatumumab in registry data?”, we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 999 papers most relevant to the query.

Screening

We screened in sources based on their abstracts that met these criteria:

Data extraction

We asked a large language model to extract each data column below from each paper.

Results

Characteristics of Included Studies

Study Study Design Registry Source Population Size Follow-up Duration Full text retrieved
Zanghì et al., 2024 Retrospective cohort, multicenter, propensity-matched Italian multiple sclerosis centers 396 (ocrelizumab: 216, ofatumumab: 180) Mean 13.2 months Yes
Zhu et al., 2022 Retrospective, multicenter, inverse probability of treatment weighting, registry MSBase 1045 ocrelizumab: median 1.8 years; cladribine: 1.1 years; natalizumab: 3.6 years Yes
Ghajarzadeh et al., 2025 Systematic review/meta-analysis Multiple No mention found No mention found No
Cunha et al., 2025 Retrospective cohort No mention found 59 No mention found No
Epstein et al., 2021 Retrospective chart review No mention found 56 2 years No

Annualized Relapse Rate

Study Treatment Annualized Relapse Rate (95% CI) Study Population Effect Size
Zanghì et al., 2024 ocrelizumab: 0.059; ofatumumab: 0.038 (p=0.185) Relapsing multiple sclerosis No significant difference
Zhu et al., 2022 ocrelizumab: 0.07; natalizumab: 0.11 Relapsing-remitting multiple sclerosis post-fingolimod ocrelizumab superior to cladribine, lower than natalizumab
Cunha et al., 2025 ocrelizumab/ofatumumab: no significant change; rituximab: 0.08 (post-switch) Post-natalizumab No significant change for ocrelizumab/ofatumumab

Confirmed Disability Progression

Study Treatment Confirmed Disability Progression Rate Time to Progression Statistical Significance
Zanghì et al., 2024 ocrelizumab/ofatumumab: 0% 12 months No difference
Zhu et al., 2022 ocrelizumab/natalizumab: no mention found No mention found No significant difference
Cunha et al., 2025 ocrelizumab/ofatumumab: no significant change; rituximab: EDSS increased No mention found No significant difference for ocrelizumab/ofatumumab

Comparative Effectiveness

Direct registry-based comparisons of ocrelizumab and ofatumumab show no significant difference in annualized relapse rate or confirmed disability progression between the two drugs over 12 months.

Registry Data Considerations

References